{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-female-genital/prescribing-information/oral-itraconazole/","result":{"pageContext":{"chapter":{"id":"754e0483-3f11-5510-9b98-7f8c44679e56","slug":"oral-itraconazole","fullItemName":"Oral itraconazole","depth":2,"htmlHeader":"<!-- begin field 98c5b09b-4ff9-4930-beb4-86d18b829a0e --><h2>Oral itraconazole</h2><!-- end field 98c5b09b-4ff9-4930-beb4-86d18b829a0e -->","summary":"","htmlStringContent":"<!-- begin item 0369f186-f539-4a6f-9569-000a1d05e9ee --><!-- end item 0369f186-f539-4a6f-9569-000a1d05e9ee -->","topic":{"id":"99e20f18-68df-560d-b5d3-b6ec31ccad61","topicId":"1a8f74c5-56a3-4356-a328-97bd2f790f35","topicName":"Candida - female genital","slug":"candida-female-genital","lastRevised":"Last revised in May 2017","chapters":[{"id":"de1ba63a-d3be-5e38-9afa-2decfb6a4104","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"70e5dc95-dca6-5aed-ba02-7677e5595791","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7785eebb-7adf-5829-8438-054465d94780","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"17acaa38-dc82-5062-9b9e-b70e43844f09","slug":"changes","fullItemName":"Changes"},{"id":"3fde567e-3066-57d8-be3e-016c389f8b94","slug":"update","fullItemName":"Update"}]},{"id":"7bdd785b-dd70-5bde-a56b-ece7a71c1890","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2aea51d9-2817-5901-8b3f-003e41a1f1b9","slug":"goals","fullItemName":"Goals"},{"id":"16c71775-c8a9-58f1-b6e8-00d83ea3e32a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"584f77ef-93e6-5c84-93b4-8331fed80193","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ffb6e4fa-b86a-5191-9bbb-c113c86952b6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cc13b04c-c8b4-5403-a61e-10f784bc17de","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8ba1a16f-d8bd-55bc-8208-17beaddd9264","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"d90c278f-fcf0-5c7c-aeab-b0decc2194dd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5d851a40-f1f9-50de-b7de-3e374a862b45","slug":"definition","fullItemName":"Definition"},{"id":"51060b0d-4f1d-5133-9645-6efc6b9ca9d8","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c7dd35c5-dc87-55a0-b15e-5fd3c5f79ede","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"bcbc381a-db1c-5df4-a8fa-cb1ce02a4ab3","slug":"complications","fullItemName":"Complications"},{"id":"2ec519a6-61da-53cb-b5c6-e53420e1f175","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"1296609f-72a1-5634-918b-eb0f9bf2b217","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"197fc582-d823-5341-813b-4d48a895ac84","slug":"assessment","fullItemName":"Assessment"},{"id":"7fa609e6-64b1-5e1e-a2fe-9d8aaae57662","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b7ed2787-e953-5da0-ba29-6ad5d5aa7138","fullItemName":"Management","slug":"management","subChapters":[{"id":"0d8e43cc-e312-572a-97eb-50ab1223bf29","slug":"uncomplicated-infection","fullItemName":"Scenario: Uncomplicated infection"},{"id":"20ef6f32-4f35-577b-af2b-0479dafd7a6f","slug":"severe-infection","fullItemName":"Scenario: Severe infection"},{"id":"19018671-1df6-546c-a24e-c0277342e2e1","slug":"recurrent-infection","fullItemName":"Scenario: Recurrent infection"},{"id":"0f525c4d-623c-5b02-9045-c7f9c57692e4","slug":"diabetes-or-immunocompromised","fullItemName":"Scenario: Diabetes or immunocompromised"},{"id":"d143d272-2856-5fad-95fe-708b221847f0","slug":"during-pregnancy","fullItemName":"Scenario: During pregnancy"}]},{"id":"fa8e2e27-5ea4-5088-86f8-65ffd101ec26","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a11071ae-b868-56f6-a390-4809b91594ea","slug":"choice-of-antifungals","fullItemName":"Choice of antifungals"},{"id":"169ff7be-fabd-556e-bdf3-92c30e390f3d","slug":"intravaginal-antifungals","fullItemName":"Intravaginal antifungals"},{"id":"cca352b0-a363-5b43-97d2-9df0dbf242b6","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"},{"id":"754e0483-3f11-5510-9b98-7f8c44679e56","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"2ae3a41b-64fa-5372-baba-bb8c04e033d8","slug":"topical-antifungals","fullItemName":"Topical antifungals"}]},{"id":"dd75ee8e-5efd-51c0-bcc2-3af7ee1253e7","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"74d9d85c-590f-5e29-a202-78d94a6f747f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d7a69713-bc5d-57da-9132-ff07c7fef62c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a8d93477-c70c-5177-92d7-e96545a6b2f7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4841d69e-1e2b-5aec-9c3b-1ea8cd8bbf08","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b3113b9f-1b0e-5987-99b4-e616eb6d128a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e41c5da-d9a8-5c0d-bb7f-f68cda4acb05","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6eb1b4a4-5ae4-5a59-8ca6-6434652b9454","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"fa8e2e27-5ea4-5088-86f8-65ffd101ec26","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"1dd8d80c-25b4-5f9a-8295-fc1b4b31efd2","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 140ab907-cc7c-4a3e-84a9-a6b400db78bf --><h3>What are the contraindications and cautions for oralitraconazole?</h3><!-- end field 140ab907-cc7c-4a3e-84a9-a6b400db78bf -->","summary":"","htmlStringContent":"<!-- begin item ee276c59-3158-4079-9d98-a6b400db7755 --><!-- begin field 689f0e11-905c-4634-aeac-a6b400db78bf --><ul><li><strong>Do not prescribe oral itraconazole to:</strong><ul><li>Women with ventricular dysfunction or a history of heart failure.</li><li>Women with acute porphyria.</li><li>Pregnant or breastfeeding women.</li><li>Children and young people (age not specified by the manufacturer).</li><li>Women taking <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/oral-itraconazole/#drug-interactions\">certain drugs</a>.</li></ul></li><li><strong>Avoid oral itraconazole or use with caution in:</strong> <ul><li>Women with hepatic impairment, a history of hepatotoxicity with other drugs, or active liver disease. <ul><li>Potentially life-threatening hepatotoxicity may occur with itraconazole.</li><li>Advise the woman to report signs of liver disease (such as anorexia, nausea and vomiting, fatigue, abdominal pain, or dark urine). Discontinue treatment if this occurs.</li><li>Monitor liver function if treatment continues for longer than one month, if the woman is receiving other hepatotoxic drugs, if there is a history of hepatotoxicity with other drugs, or if there is hepatic impairment.</li></ul></li></ul></li><li><strong>Use oral itraconazole with caution in </strong><strong>women:</strong><ul><li>At high risk of heart failure. This includes:<ul><li>Those receiving high doses and longer treatment courses.</li><li>Older women and those with cardiac disease.</li><li>Those with chronic lung disease (including chronic obstructive pulmonary disease) associated with pulmonary hypertension.</li><li>Those receiving treatment with negative inotropic drugs, for example calcium channel blockers. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/oral-itraconazole/#drug-interactions\">Drug interactions</a> for more information.</li></ul></li><li>Of childbearing potential — effective contraception should be used during treatment with itraconazole and continued until the menstrual period following the end of Itraconazole treatment.</li><li>With HIV infection and neutropenia — absorption of itraconazole reduced.</li><li>With renal impairment — there is an increased risk of heart failure, and the bioavailability of oral itraconazole is possibly reduced.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>]</p><!-- end field 689f0e11-905c-4634-aeac-a6b400db78bf --><!-- end item ee276c59-3158-4079-9d98-a6b400db7755 -->","subChapters":[]},{"id":"4c83cfe6-d2b6-59ef-a961-24d98e710bd4","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 6fa11f3d-f8ec-4c68-b86d-a6b400db9275 --><h3>What are the adverse effects of oral itraconazole?</h3><!-- end field 6fa11f3d-f8ec-4c68-b86d-a6b400db9275 -->","summary":"","htmlStringContent":"<!-- begin item 95f92aed-19ac-4590-8ba6-a6b400db9113 --><!-- begin field 55dcc99c-5db8-4a40-a3d2-a6b400db9275 --><ul><li><strong>Adverse effects </strong><strong>of oral itraconazole include:</strong><ul><li><strong>Common or very common </strong><ul><li>Abdominal pain, diarrhoea, nausea, taste disturbances, and vomiting.</li><li>Dyspnoea.</li><li>Headache.</li><li>Hepatitis.</li><li>Hypokalaemia.</li><li>Rash.</li></ul></li><li><strong>Uncommon </strong><ul><li>Constipation, dyspepsia, and flatulence.</li><li>Dizziness.</li><li>Menstrual disorder.</li><li>Myalgia.</li><li>Oedema.</li><li>Peripheral neuropathy — treatment.</li></ul></li><li><strong>Rare </strong><ul><li>Alopecia.</li><li>Visual disturbances.</li><li>Tinnitus and deafness.</li><li>Erectile dysfunction.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/oral-itraconazole/#contraindications-cautions\">Heart failure</a>.</li><li>Hypertriglyceridaemia.</li><li>Leucopenia.</li><li>Pancreatitis.</li><li>Photosensitivity, Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li><li>Urinary frequency.</li></ul></li><li><strong>Frequency unknown</strong><ul><li>Arthralgia.</li><li>Blood pressure changes.</li><li>Confusion and drowsiness.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/oral-itraconazole/#contraindications-cautions\">Hepatotoxicity</a>.</li><li>Renal impairment.</li><li>Thrombocytopenia.</li><li>Tremor.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>]</p><!-- end field 55dcc99c-5db8-4a40-a3d2-a6b400db9275 --><!-- end item 95f92aed-19ac-4590-8ba6-a6b400db9113 -->","subChapters":[]},{"id":"4a9db225-ca03-5d46-b75a-2aef43b73bdb","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 100bece9-76a4-43d0-b188-a6b400dbb659 --><h3>What drug interactions are associated with oral itraconazole?</h3><!-- end field 100bece9-76a4-43d0-b188-a6b400dbb659 -->","summary":"","htmlStringContent":"<!-- begin item afdbc9b2-097b-4f49-8183-a6b400dbb4f4 --><!-- begin field 0c596015-6f1a-4b6a-82a7-a6b400dbb659 --><ul><li><strong>Itraconazole inhibits the metabolism of drugs metabolized by the cytochrome P450 enzyme CYP3A4 (as it is a potent inhibitor of this enzyme). This may result in a higher and/or prolonged effect of these drugs, including adverse effects. </strong><ul><li><strong>The following drugs are contraindicated (or should be avoided) during treatment with itraconazole:</strong><ul><li>Aliskiren.</li><li>Apixaban.</li><li>Avanafil.</li><li>Colchicine —<strong> </strong>suspend or reduce dose of colchicine (avoid concurrent use in hepatic or renal impairment).</li><li>Domperidone — possible increased risk of ventricular arrhythmias when itraconazole is given with domperidone.</li><li>Eletriptan.</li><li>Eplerenone.</li><li>Ergot alkaloids (such as ergotamine and ergometrine) — increased risk of ergotism.</li><li>Ivabradine.</li><li>Midazolam.</li><li>Mizolastine — concurrent use with itraconazole may lead to QT prolongation and rare occurrences of Torsade de Pointes.</li><li>Pimozide — concurrent use with itraconazole may lead to QT prolongation and rare occurrences of Torsade de Pointes.</li><li>Quetiapine.</li><li>Ranolazine.</li><li>Reboxetine.</li><li>Rivaroxaban.</li><li>Sirolimus.</li><li>Statins metabolized via cytochrome P450 3A4 (atorvastatin and simvastatin) — possible increased risk of myopathy and rhabdomyolysis. If treatment with itraconazole is unavoidable, stop statin treatment during the course of treatment with itraconazole.</li><li>Vardenafil.</li></ul></li><li><strong>Concurrent treatment with itraconazole</strong><strong> and the following drugs </strong><strong>should be done with caution </strong>(concurrent use should be monitored; dose adjustments may be indicated):<ul><li>Aripiprazole.</li><li>Budesonide.</li><li>Ciclosporin.</li><li>Cilostazol.</li><li>Coumarins — there are case reports of increased international normalized ratio (INR) and bleeding when itraconazole and coumarins (such as warfarin) are used concurrently. Monitor the INR closely.</li><li>Digoxin.</li><li>Disopyramide.</li><li>Felodipine.</li><li>Fentanyl.</li><li>HIV protease inhibitors — itraconazole increases plasma concentrations of indinavir and possibly increases plasma concentrations of saquinavir. Concurrent treatment with ritonavir may increase plasma concentrations of either drug (or both).</li><li>Methadone (increased risk of ventricular arrhythmias).</li><li>Rosuvastatin.</li><li>Solifenacin.</li><li>Tacrolimus.</li></ul></li></ul></li><li><strong>Other possible drug interactions of itraconazole include:</strong><ul><li>Clopidogrel — itraconazole possibly reduces the antiplatelet effect of clopidogrel.</li><li>CYP3A4 inducers — itraconazole is mainly metabolized by CYP3A4. The plasma concentrations of itraconazole are therefore reduced by potent CYP3A4 inducers, such as rifampicin, rifabutin, and phenytoin. Similar effects are expected for other enzyme inducers, such as carbamazepine, St John's wort, and phenobarbital. Itraconazole should not be used during treatment with (and within 2 weeks of stopping) these drugs.</li></ul></li><li><strong>For a complete list of possible drug interactions of itraconazole, </strong>see the <a data-hyperlink-id=\"748b7eb4-8bb8-4115-b8ff-a98f0111063c\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) and the <a data-hyperlink-id=\"ccea270c-c689-4d62-a95a-a98f01110658\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>]</p><!-- end field 0c596015-6f1a-4b6a-82a7-a6b400dbb659 --><!-- end item afdbc9b2-097b-4f49-8183-a6b400dbb4f4 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}